Alzheimer’s disease is no longer just a medical challenge. It is a looming fiscal crisis—and one the United States is dangerously unprepared to confront.
In a recent column published in The Capitalist, Charles Sauer argued that policymakers urgently need to recognize Alzheimer’s as an economic ticking time bomb. Without a coordinated national response, the United States is heading toward a fiscal avalanche driven by demographic change, rising entitlement costs, and lost productivity.
America’s population is aging faster than its public programs can handle. For the first time in U.S. history, adults over the age of 65 will soon outnumber those under the age of 18. This top-heavy demographic structure places enormous strain on Medicare and Medicaid—programs that rely on a large, working-age population to finance benefits for retirees.
Alzheimer’s dramatically accelerates this pressure. Patients often require years of intensive care, driving Medicaid nursing-home spending sharply higher while pushing Medicare closer to insolvency. At the same time, cognitive decline pulls millions of older Americans out of the workforce just as labor shortages are worsening. Fewer workers paying into the system combined with more seniors drawing expensive benefits for longer periods is a recipe for an entitlement crisis.
If Alzheimer’s cases double by 2060—as current projections suggest—Medicare, Medicaid, and Social Security will face unsustainable fiscal stress. Policymakers will be forced to choose between deep benefit cuts or major tax increases.
The path forward is what economist Andrew Scott calls the “longevity dividend.” Rather than simply extending life, policymakers should focus on extending cognitively healthy years. Doing so would increase productivity, reduce dependence on long-term care, and slow the march toward entitlement insolvency.
The economic upside is striking. Raising healthy life expectancy by just one year is estimated to be worth roughly $566,000 per person—a massive return from policies centered on early detection and access to treatment.
China understands the economic danger posed by cognitive decline and has already launched a national Alzheimer’s strategy. The United States, by contrast, remains stuck in bureaucratic inertia—despite having world-class research, innovative diagnostics, and FDA-approved treatments already available.
A serious American response would empower primary care physicians to detect cognitive decline earlier, ensure Medicare covers new blood tests capable of identifying Alzheimer’s years before symptoms appear, and roll back Biden-era red tape that limits access to approved therapies. The newly introduced Alzheimer’s Screening and Prevention (ASAP) Act takes an important step by authorizing the Secretary of Health and Human Services to require Medicare coverage of these early-detection tests.
The political upside is just as compelling as the policy case. Recent polling shows that 87% of voters would credit President Donald Trump with a major achievement if he led a serious national effort to combat Alzheimer’s—demonstrating that good health policy can also be good politics.
Lifestyle interventions matter too. Research indicates that walking between 5,000 and 7,000 steps per day can delay Alzheimer’s decline by an average of seven years. Combined with early diagnosis and access to treatment, these practical steps can deliver meaningful economic and human benefits.
Smart policy choices today could translate into millions of Americans living longer, healthier, and more productive lives—strengthening families and stabilizing public finances. The alternative is bleak. Inaction will allow Alzheimer’s to accelerate U.S. fiscal instability while other nations move ahead with coordinated national strategies.
The United States still has time to act. But the window is closing fast.
Read more in The Capitalist by clicking here.
